Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

1.220 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pliant Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Pliant Therapeutics to Participate in Upcoming Investor Conferences
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Where Pliant Therapeutics Stands With Analysts ↗
Analysts have provided the following ratings for Pliant Therapeutics (NASDAQ:PLRX) within the last quarter: 
Via Benzinga
News headline image
Expert Ratings for Pliant Therapeutics ↗
  Within the last quarter, Pliant Therapeutics (NASDAQ:PLRX) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022 ↗
 
Via Benzinga
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Soaring Biotech Stocks That Could Climb Much Higher ↗
These drugmakers have bucked the overall market's downward trend this year and expectations are still high. 
Via The Motley Fool
News headline image
Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary/Lung Disease Mini-Symposium
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday ↗
Gainers 
Via Benzinga
Pliant Therapeutics Inc. (NASDAQ: PLRX) Climbs to New 52-Week High
Via Investor Brand Network
News headline image
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022 ↗
Upgrades 
Via Benzinga
News headline image
7 Cheap Biotech Stocks to Buy Now ↗
These cheap biotech stocks to buy offer investors a way to get ready for the inevitable comeback in the biopharmaceutical sector. 
Via InvestorPlace
News headline image
Pliant Therapeutics Secures FDA Fast Track Status For Liver Disease Drug ↗
Pliant Therapeutics (NASDAQ: PLRX) received Fast Track designation for its lead asset PLN-74809 from the U.S. Food and Drug Administration (FDA) for the potential treatment of primary sclerosing... 
Via Benzinga
News headline image
4 Analysts Have This to Say About Pliant Therapeutics ↗
Over the past 3 months, 4 analysts have published their opinion on Pliant Therapeutics (NASDAQ:PLRX) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022 ↗
Upgrades 
Via Benzinga
News headline image
The Daily Biotech Pulse: AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, Humanigen's Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth's Alzheimer's Program ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Boeing, PriceSmart And 80 Biggest Movers From Yesterday ↗
Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share. 
Via Benzinga
News headline image
Why Is Canoo Surging By 80%? 52 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Short Volatility Alert: Pliant Therapeutics, Inc. ↗
On Monday, shares of Pliant Therapeutics, Inc. (NASDAQ: PLRX) experienced volatile short activity. After the activity, the stock price went up +159.01% to $23.00. The overall sentiment for PLRX has... 
Via Benzinga
News headline image
The Daily Biotech Pulse: GSK To Supply 50M Flu Vaccine Doses To US, FDA Lifts Hold On Greenwich's Cancer Immunotherapy Trial, Connect Biopharma Sees CBP-201 Topline Data Sooner ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
What's Going On With Pliant Therapeutics Stock? ↗
Pliant Therapeutics Inc (NASDAQ: PLRX) shares are trading lower Tuesday after the company announced a proposed $150 million offering. 
Via Benzinga
News headline image
Alibaba, Zoom Video And 76 Biggest Movers From Yesterday ↗
Gainers Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media. 
Via Benzinga
News headline image
After-Hours Alert: Why Pliant Therapeutics Stock Is Moving ↗
Pliant Therapeutics Inc (NASDAQ: PLRX) shares are volatile in Monday's after-hours session after the company announced a proposed $150 million offering. 
Via Benzinga
News headline image
Dow Dips Around 90 Points; La Jolla Pharmaceutical Shares Surge ↗
U.S. stocks traded lower toward the end of trading as investors digested the recent jobs report for the month of June. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Stocks Lower Midday as Tech Slumps ↗
Stocks are lower midday, with the Dow Jones Industrial Average and Nasdaq Composite both down triple digits, as investors prepare for this week's inflation data and the start of earnings season. 
Via Talk Markets
News headline image
Pliant Therapeutics Stock Just Doubled And Hit A 10-Month High — Here's Why ↗
The company's IPF treatment is proving itself where others didn't. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.